- Arxada AG will invest CHF 20m in its industrial biotechnological plant in Kouřim, Czech Republic
- The investment will provide infrastructure debottlenecking and expanded technological options
- The investment is to support the growing customer base with technologically challenging projects
- The Kouřim site is an integral part of Arxada's future strategy, with growing demand for CDMO projects in biotech
Basel, Switzerland – Arxada AG, a global specialty chemicals business, today announces that it will invest CHF 20m (€19mln) in its industrial biotechnological plant in Kouřim, Czech Republic, which serves the contract development and manufacturing organization (CDMO) part of its Specialty Products Solutions business. This investment provides important infrastructure debottlenecking in connection with expanded technological options and the addition of significant formulation capacity necessitated by Arxada’s growing customer base.
Antje Gerber, President, Specialty Products Solutions, Arxada, said: “With this investment, we are strengthening our capacity to support our expanding customer base with their highly interesting and often technologically challenging projects.”
Lukas von Hippel, VP, CDMO Business Line, Arxada, commented: “Our site in Kouřim is an integral part of our future strategy. Following the implementation of our new strategy in May 2020, we have seen more customers seeking our support in their new projects. Our business development team together with our process development team in Kouřim can speed up development and shorten time to market by over a year in some cases.”
Zdena Cermakova, Kouřim Site Head, Arxada, added: “We are seeing growing demand for CDMO projects in biotech. Last week, one of the auditors auditing our site on behalf of a customer stated that he had never seen such a well-maintained site. This compliment raises the bar even higher, if possible.”
